FDA Approves Juvederm Voluma XC

FDA Approves Juvederm Voluma XC

To Correct Volume Loss in Cheeks

Dr. Jon Mendelsohn of Advanced Cosmetic Surgery & Laser Center Now One Of First Plastic Surgeons In Tri-State To Treat Patients

CINCINNATI, OH – November 7, 2013 —The FDA has recently approved Juvederm Voluma XC, the first and only filler approved to correct age related volume loss in the cheek area. Dr. Jon Mendelsohn of Advanced Cosmetic Surgery & Laser Center is one of the first plastic surgeons in the Tri-State to offer this treatment.

Says Mendelsohn, “Hyaluronic Acid (HA) is a naturally occurring, hydrating substance found in our skin. As we start to age, we begin losing HA, which causes the skin to lose structure and volume, often causing the cheeks to flatten out and sag. Juvederm Voluma XC is the first and only Hyaluronic Acid (HA) FDA-approved filler to instantly add volume to the cheek area, resulting in a subtle lift. It is an effective, non-surgical treatment option that can restore contour and help provide smooth, natural looking results that last up to two years, with instant results that patients can see before they leave our office. There is relatively little recovery or downtime, although patients may experience some temporary redness, bruising or swelling.”

Mendelsohn adds, “Juvederm XC has long been used to treat moderate to severe facial wrinkles and folds such as nasolabial folds or parentheses lines. The new Voluma XC is used exclusively for deep cheek injection, into three specific areas of the cheek – the Apex, Apple and Hollow, and we anticipate a large demand from our patients for this product.”

Dr. Jon E. Mendelsohn is double board certified by both the American Board of Facial & Reconstructive Surgery and also the American Board of Otolaryngology – Head & Neck Surgery. He serves as the medical director of Advanced Cosmetic Surgery & Laser Center’s new, state-of-the-art facility located in the Rookwood Tower in Hyde Park. For more information, call 513-351-FACE, or visit www.351face.com.